Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract C84: Nonclinical metabolism, disposition, pharmacokinetics, and in vitro drug-drug interaction assessment of ARQ 087, a pan-FGFR inhibitor.

Terence G. Hall, Laurie P. Volak, Karen R. Bresciano, Yunxia Wang, Chang-Rung Chen, Syed Ali, David Mckearn, Inese Smukste, Ronald E. Savage

Mol Cancer Ther (2013) 12 (11_Supplement): C84.

https://doi.org/10.1158/1535-7163.TARG-13-C84

Published: 01 November 2013

View article titled, Abstract C84: Nonclinical metabolism, disposition, pharmacokinetics, and in vitro drug-drug interaction assessment of ARQ 087, a pan-FGFR inhibitor.

Journal Articles

Abstract A278: ARQ 087, a multi-tyrosine kinase inhibitor with potent in vitro and in vivo activity in FGFR2 driven models.

Daniel Dransfield, Jennifer Lee, Carol Waghorne, Cathy Bull, Ronald E. Savage, Xiaolan Zhao, Shipeng Yuan, Edward Chang, Enkeleda Nakuci, Sudharshan Eathiraj, Susan Cornell-Kennon, Xiubin Gu, Syed Ali, Chang-Rung Chen

Mol Cancer Ther (2013) 12 (11_Supplement): A278.

https://doi.org/10.1158/1535-7163.TARG-13-A278

Published: 01 November 2013

View article titled, Abstract A278: ARQ 087, a multi-tyrosine kinase inhibitor with potent in vitro and in vivo activity in FGFR2 driven models.

Journal Articles

Abstract A281: Exploratory study on predictive biomarkers for ARQ 092, a novel selective pan-AKT inhibitor.

Yi Yu, Rebecca Carazza, Chang-Rung Chen, Takeshi Isoyama, Koichi Tazaki, Kosaku Fujiwara, Daniel T. Dransfield

Mol Cancer Ther (2013) 12 (11_Supplement): A281.

https://doi.org/10.1158/1535-7163.TARG-13-A281

Published: 01 November 2013

View article titled, Abstract A281: Exploratory study on predictive biomarkers for ARQ 092, a novel selective pan-AKT inhibitor.

Journal Articles

Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK.

Nivedita D. Namdev, Susan Cornell-Kennon, Yi Yu, Jason Hill, Cathy Bull, Laurie Volak, Jianqiang Wang, Deirdre Lowe, Xuibin Gu, Steffi Koerner, Magdi Moussa, David Vensel, Yanbin Liu, Hui Wu, Chang-Rung Chen, Daniel T. Dransfield, Mark A. Ashwell

Mol Cancer Ther (2013) 12 (11_Supplement): B270.

https://doi.org/10.1158/1535-7163.TARG-13-B270

Published: 01 November 2013

View article titled, Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK.

Journal Articles

Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.

Thomas C.K. Chan, Jean-Marc Lapierre, Mark A. Ashwell, Dennis S. France, Chang-Rung Chen, Susan Cornell-Kennon, Cathy Bull, Sudhi Eathiraj, Rocio Palma, Yanbin Liu, Sapna Makhija, Carol Waghorne, Ron Savage, Kosaku Fujiwara

Mol Cancer Ther (2011) 10 (11_Supplement): A230.

https://doi.org/10.1158/1535-7163.TARG-11-A230

Published: 12 November 2011

View article titled, Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.

Journal Articles

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Neru Munshi, Sébastien Jeay, Youzhi Li, Chang-Rung Chen, Dennis S. France, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, David S. Leggett, Chiang J. Li

Mol Cancer Ther (2010) 9 (6): 1544–1553.

https://doi.org/10.1158/1535-7163.MCT-09-1173

Published: 09 June 2010

View article titled, ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Includes: Supplementary data

Journal Articles

Abstract A139: Discovery and biological profiling of potent fibroblast growth factor receptor (FGFR) kinase inhibitors derived from in silico design with in vivo antitumor activity against FGFR2‐dependent human tumors

Mol Cancer Ther (2009) 8 (12_Supplement): A139.

https://doi.org/10.1158/1535-7163.TARG-09-A139

Published: 10 December 2009

View article titled, Abstract A139: Discovery and biological profiling of potent fibroblast growth factor receptor (FGFR) kinase inhibitors derived from <em>in silico</em> design with <em>in vivo</em> antitumor activity against FGFR2‐dependent human tumors

NARROW

Abstract C84: Nonclinical metabolism, disposition, pharmacokinetics, and in vitro drug-drug interaction assessment of ARQ 087, a pan-FGFR inhibitor.

Abstract A278: ARQ 087, a multi-tyrosine kinase inhibitor with potent in vitro and in vivo activity in FGFR2 driven models.

Abstract A281: Exploratory study on predictive biomarkers for ARQ 092, a novel selective pan-AKT inhibitor.

Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK.

Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Abstract A139: Discovery and biological profiling of potent fibroblast growth factor receptor (FGFR) kinase inhibitors derived from in silico design with in vivo antitumor activity against FGFR2‐dependent human tumors

Email alerts

AACR Journals

Abstract C84: Nonclinical metabolism, disposition, pharmacokinetics, and in vitro drug-drug interaction assessment of ARQ 087, a pan-FGFR inhibitor.

Abstract A278: ARQ 087, a multi-tyrosine kinase inhibitor with potent in vitro and in vivo activity in FGFR2 driven models.

Abstract A281: Exploratory study on predictive biomarkers for ARQ 092, a novel selective pan-AKT inhibitor.

Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK.

Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Abstract A139: Discovery and biological profiling of potent fibroblast growth factor receptor (FGFR) kinase inhibitors derived from in silico design with in vivo antitumor activity against FGFR2‐dependent human tumors

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only